ArticleJournal of clinical medicine2023

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice.

Magdalena Knetki-Wróblewska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.